sur EnVVeno Medical Corporation (NASDAQ:NVNO)
Positive Interim Results for enVVeno Medical’s VenoValve in SAVVE Trial
enVVeno Medical Corporation (NASDAQ: NVNO) announced positive interim results from its SAVVE U.S. pivotal trial for the VenoValve. Presented at the 2024 Society for Vascular Surgery Annual Meeting, the data highlights significant clinical improvements in venous ulcer healing.
The trial included 21 patients with 30 venous ulcers. At the one-year mark, 91% of ulcers had either fully healed or improved. Specifically, 100% of ulcers present for one year or less before surgery had completely healed. For ulcers older than one year, 89% showed full healing or improvement.
No recurrences were observed among fully healed cases. enVVeno is on track to file for FDA approval of the VenoValve in Q4 2024, with sufficient capital to fund operations through the end of 2025.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de EnVVeno Medical Corporation